Tremfya launched for psoriasis

Janssen has launched guselkumab (Tremfya) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Janssen says that guselkumab is the first biologic to “selectively target interleukin-23, a key protein that initiates a specific immune inflammatory response”.

Recommended

Warfarin may cut cancer risk

Research suggests warfarin may have anti-cancer potential. Could this have implications for anticoagulation patients?

Quadrivalent flu jab launched

Sanofi Pasteur recently launched a quadrivalent influenza vaccine in the UK that protects against two A and two B strain...